While still robust, CSL half-year results last Weds revealed impact of an “alarming” fall off in 'flu vax rates, especially ...

Takeda’s plasma-derived therapies (PDT) business tackles supply-chain challenges to expand access to life-saving treatments, ...

California Plasma Coalition (CalPlasma) is working to address barriers to source plasma donations and help save more lives.

Australian biopharmaceutical company CSL reported a drop in vaccine sales due to falling immunization rates in the U.S., its largest market. The decline contributed to lower-than-expected profits, ...

Australian biopharmaceutical company CSL posted higher first-half profits as growth in its main blood-plasma business helped offset weaker flu vaccine sales, which were hit by "significantly" low ...

The CSL Ltd (ASX: CSL) share price will be watched closely today after the biotech giant released its half year ...

CSL (ASX:CSL) has reported a net profit after tax of $2.01 billion for the six months to the ned of December 2024, up 7 per ...

CEO Paul McKenzie announced a reaffirmation of guidance for fiscal 2025, targeting NPATA growth of 10% to 13%. He highlighted strong results from CSL Behring and growth in CSL Vifor, while ...

Q: Could you provide more details on the decoupling of CSL's contribution and the underlying trends in plasma? A: Christopher Simon, CEO: CSL is performing as expected, with the transition on track.

“CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in ...

Haemonetics updated its hospital revenue guidance to 24% to 26% reported growth and 12% to 14% organic growth, driven by strong adoption of hemostasis cartridges and vascular closure devices.